Effects of Sunitinib in Combination with Octreotide LAR for Patients with Advanced Pancreatic Neuroendocrine Tumor which Failed Sunitinib or Octreotide LAR Alone

被引：0
|
作者：
Ying, H. [1 ]
Cheng, Y. [1 ]
Sun, Z. [1 ]
Xue, H. [1 ]
Meng, C. [1 ]
机构：
[1] Beijing Union Med Coll Hosp, Beijing, Peoples R China
来源：
NEUROENDOCRINOLOGY | 2014年 / 99卷 / 3-4期
关键词：
pnet; sunitinib; octreotide lar; combination; efficacy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
M10
引用
收藏
页码：281 / 281
页数：1
相关论文
共 50 条
  • [1] Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor
    Grande, Enrique
    Jose Diez, Juan
    Pachon, Vanessa
    Angeles Vaz, Maria
    Longo, Federico
    Guillen, Carmen
    Luisa Garcia de Paredes, Maria
    Carrato, Alfredo
    ANTI-CANCER DRUGS, 2011, 22 (05) : 477 - 479
  • [2] A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
    Bendell, Johanna C.
    Zakari, Ahmed
    Lang, Evan
    Waterhouse, David
    Flora, Douglas
    Alguire, Kathryn
    McCleod, Michael
    Peacock, Nancy
    Ruehlman, Peter
    Lane, Cassie M.
    Earwood, Chris
    Shih, Kent
    CANCER INVESTIGATION, 2016, 34 (05) : 213 - 219
  • [3] Antiproliferative activity of octreotide LAR in advanced neuroendocrine tumors.
    Toumpanakis, Christos
    Laskaratos, Faidon
    Maragkoudakis, Emmanouil
    Naik, Keval
    Oikonomopoulos, Nikolaos
    Walker, Martin
    Grant, Lee
    Meyer, Tim
    Caplin, Martyn E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2.
    Wolin, E. M.
    Fazio, N.
    Saletan, S.
    Winkler, R. E.
    Panneerselvam, A.
    Kvols, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A CASE REPORT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMOR TREATED WITH CHEMOTHERAPY FOR CISPLATIN CONTAINING RESIMEN FOLLOWED BY EVEROLIMUS IN COMBINATION WITH OCTREOTIDE LAR
    Suzuki, K.
    Kanno, S.
    Wakasugi, H.
    Itoh, M.
    Fujii, K.
    Goto, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 149 - 149
  • [6] Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors
    Woltering, EA
    Mamikunian, PM
    Zietz, S
    Krutzik, SR
    Go, VLW
    Vinik, AI
    Vinik, E
    O'Dorisio, TM
    Mamikunian, G
    PANCREAS, 2005, 31 (04) : 392 - 400
  • [7] A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib
    Hironori Kitade
    Koushiro Ohtsubo
    Kengo Hokkoku
    Mitsue Mori
    Robert Yoshiyuki Osamura
    Hiroshi Sakuma
    Masuo Nakai
    Seiji Yano
    International Cancer Conference Journal, 2019, 8 : 24 - 28
  • [8] A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib
    Kitade, Hironori
    Ohtsubo, Koushiro
    Hokkoku, Kengo
    Mori, Mitsue
    Osamura, Robert Yoshiyuki
    Sakuma, Hiroshi
    Nakai, Masuo
    Yano, Seiji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2019, 8 (01) : 24 - 28
  • [9] Octreotide acetate (LAR) dose effect on plasma octreotide levels: Impact on neuroendocrine tumor management
    Woltering, E
    Mamikunian, PM
    Zeitz, S
    Krutzik, SR
    Go, VLW
    Vinik, AI
    Vinik, E
    O'Dorisio, T
    Mamikunian, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 235S - 235S
  • [10] Predictive Factors for Antiproliferative Activity of Octreotide LAR in Advanced Neuroendocrine Tumors
    Toumpanakis, C.
    Laskaratos, F.
    Maragkoudakis, E.
    Naik, K.
    Oikonomopoulos, N.
    Walker, M.
    Grant, L.
    Meyer, T.
    Caplin, M.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 126 - 126
12345